Risk-Adapted Therapy With Three or Six Cycles of Doxorubicin/Bleomycin/Vinblastine/Dacarbazine Plus Involved-Field Radiation Therapy in Hodgkin Lymphoma, Based on Prognosis at Diagnosis and Early Response: Results From the GATLA Study

Pavlovsky, Santiago; Corrado, Claudia; Pavlovsky, Miguel Arturo; Prates, María Virginia; Zoppegno, Lucia; Giunta, Mario; Cerutti, Ider; Palomino, Elsa; Pagani, Fernando; Lastiri, Francisco; Bär, Daniel; Bezares, Raimundo F.; Avila, Graciela

doi:10.3816/clml.2010.n.028

Cited by 3 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this reason, and to make the study groups comparable (in the previous trial, GATLA employed different definitions for early‐ and advanced‐stage disease) PFS and OS at 3 years was re‐analysed for all 584 patients enrolled in LH‐96 using the definitions of early‐ and advanced‐stage disease specified for the LH‐05 study. PFS at 3 years for early‐stage disease was shown to be 87% vs. 86% for LH‐96 vs. LH‐05 and 72% vs. 77% for advanced‐stage disease (Pavlovsky et al, ). The main difference between these two studies was the intensity of therapy received by patients.…”

Section: Discussionmentioning

confidence: 99%

“…Patients with Stage IIIB and IV or bulky disease, and those early‐stage patients who did not achieve a CR after three cycles of ABVD, continued therapy to receive a total of six cycles of ABVD plus 30 Gy IFRT to bulky areas identified at diagnosis, or to those areas remaining positron emission tomography (PET) positive following the third cycle of ABVD. The 5‐year event‐free survival rate was 89% for those patients with Stage IA–IIIA and early CR, compared with 66% for those with a partial response (PR) after three cycles of ABVD who continued treatment, and 72% for the advanced stage group ( P < 0·001) (Pavlovsky et al, ).…”

mentioning

confidence: 99%

“…The cooperative group, Grupo Argentino de Tratamiento de Leucemia Aguda (GATLA) has previously published data relating to the use of risk‐adapted therapy for patients with cHL treated with three or six cycles of ABVD plus involved‐field radiation therapy (IFRT), based on stage at diagnosis and early response (LH‐96) (Pavlovsky et al, ). Patients with Stage IA–IIIA disease without bulky areas who achieved a complete remission (CR), as evaluated by computed tomography (CT) scan after three cycles of ABVD, were consolidated with IFRT at 25 Gy.…”

mentioning

confidence: 99%

See 2 more Smart Citations

PET‐adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH‐05 trial

et al. 2019

Self Cite

View full text Add to dashboard Cite

Summary The role of Ann Arbor staging in determining treatment intensity after achieving a negative positron emission tomography (PET) has not been established in classical Hodgkin lymphoma (cHL). Patients with stage I–IV cHL, received three cycles of ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and an interim PET scan (PET3). PET3‐negative patients received no further therapy. PET3‐positive patients received three additional cycles of ABVD plus involved‐field radiation therapy or salvage chemotherapy, if refractory to ABVD, and were re‐evaluated by PET scan (PET6). Study endpoints were 3‐year progression‐free survival (PFS) and overall survival (OS) rates. Two hundred and thirty‐nine patients with early‐stage and 138 with advanced‐stage were evaluable. Overall, 260 patients (70%) were PET3‐negative and had higher 3‐year PFS (90% vs. 65%; P < 0·0001) and OS (98% vs. 92%; P = 0·007) rates than PET3‐positive patients. All PET3‐negative patients, regardless of disease stage at diagnosis, achieved similarly good PFS (90–91%; P = 0·76) and OS (97–99%). The only independent prognostic factor for PFS was PET3‐negativity (Hazard ratio 3·8; 95% confidence interval 2·4–6·3; P < 0·0001). This study suggests that cHL patients who achieve a negative PET3 following ABVD have an excellent outcome, regardless of stage at diagnosis. An appropriately powered, phase III trial will be necessary to confirm these findings.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

PET‐adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH‐05 trial

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Most of these studies will use PET response to help guide therapy decisions, similar to the GATLA study in Argentina [33]. In the first study, from the Cancer and Leukemia Group B (CALGB), patients will receive ABVD for two cycles followed by PET re-staging.…”

Section: Outcomes After Modifications In Therapymentioning

confidence: 99%

“…The 2010 GATLA study from Argentina reported a single-arm, phase II CMT risk/response-adapted approach [33]. Patients under the age of 75 years at all stages of HL were treated with three cycles of ABVD followed by PET re-staging.…”

Section: Outcomes After Modifications In Therapymentioning

confidence: 99%

Can Low-Risk, Early-Stage Patients with Hodgkin Lymphoma Be Spared Radiotherapy?

Coté

Canellos

2011

Curr Hematol Malig Rep

View full text Add to dashboard Cite

Advances in the treatment of Hodgkin lymphoma since about 1970 have led to a remarkable improvement in the long-term outcomes of what was once considered an incurable disease. The prolonged survival of cured patients has revealed new issues concerning the toxicity of successful therapy, however, including an increased risk of secondary malignancies and end-organ damage such as heart disease. This concern has led to the clinical research question of whether the de-escalation of treatment intensity could allow high cure rates to continue with less long-term toxicity. In young patients with favorable early-stage disease, the challenge has been to use systemic therapy while omitting radiation therapy as part of the initial treatment. This review briefly summarizes past data and updates readers regarding recent publications on this topic.

show abstract

Clinical characteristics of Australian treatment‐naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry

Nguyen

Wellard

Chung

et al. 2022

European J of Haematology

View full text Add to dashboard Cite

Comprehensive clinical characteristics of Australian patients with classical Hodgkin Lymphoma (cHL) have not previously been systematically collected and described. We report real‐world data of 498 eligible patients from the first 5 years of the Lymphoma and Related Diseases Registry (LaRDR), including baseline characteristics, histologic subtype, and treatment patterns in first‐line therapy. Patient demographics and distribution of histopathological subtypes of cHL are similar to reported international cohorts. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) was the most common therapy for both early and advanced‐stage disease, and 48% of patients with the early‐stage disease received radiotherapy. Treatment patterns are consistent with international guidelines. In comorbid patients ≥60 years of age with advanced‐stage disease, there is greater variation in treatment. In patients with a recorded response, the objective response rate (ORR) was 96% in early‐stage disease, and 88% in advanced‐stage disease. Early progression‐free survival data suggest Australian patients with cHL have good outcomes, similar to other international studies.

show abstract

Risk-Adapted Therapy With Three or Six Cycles of Doxorubicin/Bleomycin/Vinblastine/Dacarbazine Plus Involved-Field Radiation Therapy in Hodgkin Lymphoma, Based on Prognosis at Diagnosis and Early Response: Results From the GATLA Study

Cited by 3 publications

References 22 publications

PET‐adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH‐05 trial

PET‐adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH‐05 trial

Can Low-Risk, Early-Stage Patients with Hodgkin Lymphoma Be Spared Radiotherapy?

Clinical characteristics of Australian treatment‐naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry

Contact Info

Product

Resources

About